- Home
- JVSA vs IOVA Comparison
JVSA vs IOVA Comparison
Compare JVSA & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVSA
- IOVA
- Stock Information
- Founded
- JVSA 2021
- IOVA 2007
- Country
- JVSA Hong Kong
- IOVA United States
- Employees
- JVSA N/A
- IOVA N/A
- Industry
- JVSA
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JVSA
- IOVA Health Care
- Exchange
- JVSA NYSE
- IOVA Nasdaq
- Market Cap
- JVSA 82.7M
- IOVA 1.0B
- IPO Year
- JVSA 2024
- IOVA N/A
- Fundamental
- Price
- JVSA $10.79
- IOVA $3.17
- Analyst Decision
- JVSA
- IOVA Strong Buy
- Analyst Count
- JVSA 0
- IOVA 9
- Target Price
- JVSA N/A
- IOVA $18.22
- AVG Volume (30 Days)
- JVSA 29.4K
- IOVA 9.3M
- Earning Date
- JVSA 01-01-0001
- IOVA 05-08-2025
- Dividend Yield
- JVSA N/A
- IOVA N/A
- EPS Growth
- JVSA N/A
- IOVA N/A
- EPS
- JVSA 0.28
- IOVA N/A
- Revenue
- JVSA N/A
- IOVA $164,070,000.00
- Revenue This Year
- JVSA N/A
- IOVA $182.20
- Revenue Next Year
- JVSA N/A
- IOVA $62.10
- P/E Ratio
- JVSA $39.13
- IOVA N/A
- Revenue Growth
- JVSA N/A
- IOVA 13698.99
- 52 Week Low
- JVSA $10.09
- IOVA $2.70
- 52 Week High
- JVSA $10.78
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- JVSA N/A
- IOVA 43.38
- Support Level
- JVSA N/A
- IOVA $3.02
- Resistance Level
- JVSA N/A
- IOVA $3.73
- Average True Range (ATR)
- JVSA 0.00
- IOVA 0.25
- MACD
- JVSA 0.00
- IOVA 0.01
- Stochastic Oscillator
- JVSA 0.00
- IOVA 25.33
About JVSA JVSPAC ACQUISITION CORP
JVSPAC Acquisition Corp is blank check company.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.